OncoAssure develops clinically validated molecular diagnostic tests that use concise gene panels to predict cancer aggressiveness. By combining transcriptomic profiling with mathematical modeling, the company creates RT‑qPCR‑based IVD assays that can be run on standard hospital laboratory equipment, delivering rapid, reproducible prognostic information to oncologists and pathologists.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer management often lacks rapid, reliable molecular biomarkers that can predict disease progression, leading to delayed or suboptimal treatment decisions, especially after biopsy procedures.
Solution
OncoAssure develops clinically validated biomarkers by integrating transcriptomic profiling with mathematical modeling to pinpoint upstream “master driver” genes that indicate cancer aggressiveness. The company translates these gene panels into highly sensitive RT‑qPCR in‑vitro diagnostic (IVD) assays that can be performed in local hospital laboratories using standard equipment. By focusing on a concise set of driver genes, the tests provide prognostic information beyond conventional pathology, enabling clinicians to make timely, evidence‑based treatment choices. The assays undergo rigorous analytical and clinical validation to ensure reproducibility and accuracy. OncoAssure’s platform supports a pipeline of tests for multiple cancer types, extending the benefits of precise molecular diagnostics across oncology.
Target Audience
Primary customers are oncologists, pathologists, and hospital laboratory teams seeking reliable molecular tests to guide treatment decisions, as well as diagnostic labs that require easy‑to‑implement RT‑qPCR assays.
Features
- Identification of concise “master driver” gene panels that regulate downstream prognostic markers
- Proprietary bioinformatic workflow combining transcriptomics and mathematical modeling
- RT‑qPCR‑based IVD assays designed for use on standard laboratory instruments
- Fully validated reagents and protocols ensuring high sensitivity and reproducibility
- Tests optimized for rapid turnaround to support timely clinical decision‑making
- Ongoing pipeline development for additional cancers such as melanoma, bladder, squamous cell carcinoma, and oesophageal cancer